Effects of Continuous Treatment With Rifaximin and Probiotics on the Gut Microbiota of Patients With IBS-D

Summary

We will use the latest Rome IV criteria to recruit IBS-D patients and evaluate the effects of repeated treatment with rifaximin and sequential treatment with rifaximin and probiotics on different symptoms and quality of life. High-throughput sequencing combined with real-time quantitative PCR will be used to comprehensively analyze the effects of different drugs on intestinal flora. The study has important guiding significance for the treatment of patients with IBS-D.

Conditions

• IBS - Irritable Bowel Syndrome
• Gut Microbiota

Interventions

DRUG

Rifaximin

A non-aminoglycoside intestinal antibiotic, 400mg, twice one day for 2 weeks.

DRUG

Probiotic Formula

A probiotic called Enterococcus faecium, 500mg, triple one day for 4 weeks.

DRUG

Placebo oral tablet

Placebo oral tablet that has no therapeutic effect

Sponsors & Collaborators

• Sir Run Run Shaw Hospital

  collaborator OTHER

• The First Affiliated Hospital of Zhejiang Chinese Medical University

  collaborator OTHER

• RenJi Hospital

  collaborator OTHER

• Peking Union Medical College Hospital

  collaborator OTHER

• First Affiliated Hospital of Wenzhou Medical University

  collaborator OTHER

• The Central Hospital of Lishui City

  collaborator OTHER

• Second Affiliated Hospital, School of Medicine, Zhejiang University

  lead OTHER

Principal Investigators

• Liangjing Wang, Ph.D · Second Affiliated Hospital, School of Medicine, Zhejiang University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

85 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-05-10

Primary Completion

2022-06-30

Completion

2022-12-31

Countries

• China

Study Locations